BioView

Company Overview

Snapshot

Founded in August 1998 by Yuval Harari, BioView operates with 11–50 employees. The company has raised a total of $8.33M across two funding rounds. BioView became public on TASE in July 2006.

Business overview

BioView develops, manufactures, and markets automated cell-imaging and analysis solutions for cytology, cytogenetic, pathology, clinical, and research laboratories. The company's core technology utilizes proprietary imaging, analysis, and review systems that control fully motorized fluorescent and bright-field microscopes with high-resolution cameras. This automates review, analysis, and reporting processes, reducing turnaround times for labor-intensive tests. BioView's products, including the DUET imaging and analysis platform, serve the Health Tech & Life Sciences sector, with FDA-cleared clinical applications for cancer detection, diagnosis, and genetic aberration detection, alongside web review solutions.

Strategic signal

In January 2026, BioView signed a memorandum of understanding to sell its LiquidView operations to a NASDAQ-listed company. This strategic move indicates a potential restructuring or divestment of a specific business unit, allowing BioView to potentially focus on other core areas or generate capital for new initiatives, signaling a significant shift in its operational strategy.

Company Intelligence Q&A

What is BioView's primary focus?

BioView specializes in developing, manufacturing, and marketing automated cell-imaging and analysis solutions for various laboratory and clinical applications, including cytology, cytogenetics, pathology, and research.

When did BioView go public?

BioView became a public company, listing on the TASE, in July 2006.

What significant agreement did BioView sign in January 2026?

In January 2026, BioView signed a memorandum of understanding for the sale of its LiquidView operations to a NASDAQ-listed company.

Has BioView collaborated with other companies on technology development?

Yes, in October 2019, BioView collaborated with RSIP Vision to use artificial intelligence for chromosome classification to improve genetic testing results. Additionally, in March 2018, BioView announced a collaboration with Vortex Biosciences to develop an integrated workflow for clinical biomarker identification on circulating tumor cells.

What regulatory approvals does BioView hold for its products?

BioView's DUET imaging and analysis platform has received FDA clearance for several FISH applications for cancer detection and diagnosis. The company's products also hold CE marking and approvals from Korean, Australian, and Thai FDA authorities.